Weekly insulin therapy
Pro Research Analysisby 
Searched over 200M research papers
Weekly Insulin Therapy: Advances and Key Insights
Weekly Insulin Therapy: Insulin Icodec and Efsitora Alfa
Recent developments in diabetes care have led to the creation of once-weekly basal insulin formulations, notably insulin icodec and insulin efsitora alfa. These new insulins are designed to provide a longer and more stable insulin exposure, aiming to simplify treatment regimens and improve adherence for people with diabetes. Clinical trials have shown that both icodec and efsitora alfa offer glycemic control comparable to traditional once-daily basal insulins, with similar risks of hypoglycemia and adverse events 1234+4 MORE.
Efficacy and Safety of Once-Weekly Insulin
Multiple studies have demonstrated that once-weekly insulin icodec is as effective as once-daily insulin glargine in lowering blood sugar levels in people with type 2 diabetes, including those who have not previously used insulin. The reduction in HbA1c and the rates of hypoglycemia were similar between weekly and daily regimens, and most adverse events were mild 678. Phase 2 and 3 trials for both icodec and efsitora alfa confirm these findings, supporting the safety and efficacy of weekly insulin therapy 1234+1 MORE.
Patient Adherence, Satisfaction, and Quality of Life
A major advantage of weekly insulin therapy is the potential to improve patient adherence and satisfaction by reducing the number of injections and simplifying the treatment routine. This is particularly important for people who struggle with daily injections due to fear of hypoglycemia, treatment complexity, or social stigma 1234. Surveys among people with type 1 diabetes also show a strong preference for weekly over daily basal insulin when other treatment features are equal, with 73% favoring the weekly option . Improved adherence could lead to better long-term outcomes and quality of life 1234+1 MORE.
Weekly Insulin in Type 1 Diabetes: Benefits and Limitations
While most research has focused on type 2 diabetes, there is growing interest in using weekly insulins for type 1 diabetes. Meta-analyses indicate that once-daily insulin may provide slightly better HbA1c reduction than weekly insulin, but fasting blood glucose control is similar between the two. Weekly insulin is associated with more injection site reactions and some increase in adverse events, but offers the benefit of fewer injections and potentially better adherence. Treatment decisions should be individualized, considering the balance between convenience, glycemic control, and side effects 2510.
Practical Considerations and Future Directions
Weekly insulin therapy represents a significant step forward in diabetes management, especially for those with type 2 diabetes who face barriers to daily injections. Ongoing phase 3 trials and real-world studies will further clarify the long-term benefits, risks, and best practices for using these new insulins in both type 1 and type 2 diabetes 1234+1 MORE.
Conclusion
Once-weekly insulin formulations like icodec and efsitora alfa are transforming diabetes care by offering effective glycemic control with fewer injections and potentially better adherence. While safety and efficacy are comparable to daily insulins, patient preferences and individual risk factors should guide therapy choices. As more data emerge, weekly insulin therapy may become a standard option for many people with diabetes, improving both clinical outcomes and quality of life.
Sources and full results
Most relevant research papers on this topic